|Table of Contents|

Research progress of histone deacetylase inhibitors in breast cancer

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2024 24
Page:
4674-4679
Research Field:
Publishing date:

Info

Title:
Research progress of histone deacetylase inhibitors in breast cancer
Author(s):
DU Yanan1; LI Rutian2; XIE Li2
1.Medical School of Nanjing University,Jiangsu Nanjing 210093,China;2.Nanjing Drum Tower Hospital,the Affiliated Hospital of Nanjing University Medical School,Jiangsu Nanjing 210008,China.
Keywords:
histone deacetylase inhibitors (HDACi); deacetylation; primary breast cancer; Chidamide
PACS:
R737.9
DOI:
10.3969/j.issn.1672-4992.2024.24.014
Abstract:
Breast cancer is a common cancer in women and poses a serious threat to women's health.Histone deacetylase (HDAC) can regulate the relationship between acetylation and deacetylation of histones in the human body,thereby regulating cell proliferation and other phenotypes.Previous studies have suggested that abnormal histone acetylation is associated with the occurrence and development of breast cancer.This article reviews the research progress of histone deacetylase inhibitors (HDACi) in the treatment of breast cancer.By deeply understanding the mechanism of action of histone deacetylase inhibitors and their application in the treatment of breast cancer,it is found that histone deacetylase inhibitors have shown promising prospects in the treatment of breast cancer.The aim of this article is to explore the mechanism of action of histone deacetylase inhibitors,clinical trial results,and their impact on the treatment of breast cancer,providing directions for the future application of these drugs in the treatment of breast cancer.

References:

［1］ BRAY F,LAVERSANNE M,SUNG H,et al.Global cancer statistics 2022:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］.CA Cancer J Clin,2024,74(3):229-263.
［2］ HUANG H,SABARI BR,GARCIA BA,et al.SnapShot:histone modifications［J］.Cell,2014,159(2):458-458.e1.
［3］ MORAN B,DAVERN M,REYNOLDS JV,et al.The impact of histone deacetylase inhibitors on immune cells and implications for cancer therapy［J］.Cancer Lett,2023,559:216121.
［4］ GEFFEN Y,ANAND S,AKIYAMA Y,et al.Pan-cancer analysis of post-translational modifications reveals shared patterns of protein regulation［J］.Cell,2023,186(18):3945-3967.e26.
［5］ PHILLIPS GD,FIELDS CT,LI G,et al.Dual targeting of HER2-positive cancer with trastuzumab emtansine and pertuzumab:critical role for neuregulin blockade in antitumor response to combination therapy［J］.Clin Cancer Res,2014,20(2):456-468.
［6］ SALEH Z,MOCCIA MC,LADD Z,et al.Pancreatic neuroendocrine tumors:Signaling pathways and epigenetic regulation［J］.Int J Mol Sci,2024,25(2):1331.
［7］ ZHAO S,ALLIS CD,WANG GG.The language of chromatin modification in human cancers［J］.Nat Rev Cancer,2021,21(7):413-430.
［8］ RODRIGUEZ-PAREDES M,ESTELLER M.Cancer epigenetics reaches mainstream oncology［J］.Nat Med,2011,17(3):330-339.
［9］ 冯元莹，邓怡林，史业辉.HDAC抑制剂调控乳腺癌细胞HER-2表达的研究进展［J］.现代肿瘤医学，2022,30（13）：2475-2478. FENG Yuanying，DENG Yilin，SHI Yehui.Advances in the regulation of HER-2 expression in breast cancer cells by HDAC inhibitors［J］.Modern Oncology,2022,30（13）：2475-2478.
［10］ 林静,李晓晖,黄美玲.新型环四肽HDAC抑制剂的化学合成及其对乳腺癌细胞增殖和迁移的抑制作用［J］.现代肿瘤医学，2022,30（16）：2908-2912. LIN Jing,LI Xiaohui,HUANG Meiling.Inhibitory effect of a novel synthetic cyclic tetra-peptide HDAC inhibitor on proliferation and migration of breast cancer cells［J］.Modern Oncology,2022,30（16）：2908-2912.
［11］ EOT-HOULLIER G,FULCRAND G,MAGNAGHI-JAULIN L,et al.Histone deacetylase inhibitors and genomic instability［J］.Cancer Lett,2009,274(2):169-176.
［12］ LIU Z,JING Q,WANG Y,et al.The short-term effect of histone deacetylase inhibitors,chidamide and valproic acid,on the NF-κB pathway in multiple myeloma cells［J］.Int J Mol Med,2019,43(1):285-293.
［13］ GUAN XW,WANG HQ,BAN WW,et al.Novel HDAC inhibitor Chidamide synergizes with Rituximab to inhibit diffuse large B-cell lymphoma tumour growth by upregulating CD20［J］.Cell Death Dis,2020,11(1):20.
［14］ WAWRUSZAK A,BORKIEWICZ L,OKON E,et al.Vorinostat (SAHA) and breast cancer:An overview［J］.Cancers(Basel),2021,13(18):4700.
［15］ SHANKAR S,DAVIS R,SINGH KP,et al.Suberoylanilide hydroxamic acid (Zolinza/vorinostat) sensitizes TRAIL-resistant breast cancer cells orthotopically implanted in BALB/c nude mice［J］.Mol Cancer Ther,2009,8(6):1596-1605.
［16］ LAENGLE J,KABILJO J,HUNTER L,et al.Histone deacetylase inhibitors valproic acid and vorinostat enhance trastuzumab-mediated antibody-dependent cell-mediated phagocytosis［J］.J Immunother Cancer,2020,8(1):e000195.
［17］ TERRANOVA-BARBERIO M,PAWLOWSKA N,DHAWAN M,et al.Exhausted T cell signature predicts immunotherapy response in ER-positive breast cancer［J］.Nat Commun,2020,11(1):3584.
［18］ SURAWEERA A,O' BYRNE KJ,RICHARD DJ.Combination therapy with histone deacetylase inhibitors (HDACi) for the treatment of cancer:Achieving the full therapeutic potential of HDACi［J］.Front Oncol,2018,8:92.
［19］ 彭晓丹,诸梦露,高绿芬,等.FK228和雷帕霉素协同促进人乳腺癌细胞凋亡和细胞周期阻滞［J］.中国病理生理杂志,2015,31(04):577-584. PENG XD,ZHU ML,GAO LF,et al.Combination therapy of FK228 with rapamycin synergistically promotes human breast cancer cell apoptosis by DNA damage and cell cycle arrest［J］.Chinese Journal of Pathophysiology,2015,31(04):577-584.
［20］ PATTARAWAT P,WALLACE S,PFISTERER B,et al.Formulation of a triple combination gemcitabine plus romidepsin+cisplatin regimen to efficaciously and safely control triple-negative breast cancer tumor development［J］.Cancer Chemother Pharmacol,2020,85(1):141-152.
［21］ SHARMA P,ABRAMSON VG,O' DEA AP,et al.Romidepsin (HDACi) plus cisplatin and nivolumab triplet combination in patients with metastatic triple negative breast cancer (mTNBC)［J］.Journal of Clinical Oncology,2021,39:1076.
［22］ GARNOCK-JONES KP.Panobinostat:first global approval［J］.Drugs,2015,75(6):695-704.
［23］ TATE CR,RHODES LV,SEGAR HC,et al.Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat［J］.Breast Cancer Res,2012,14(3):R79.
［24］ TAN WW,ALLRED JB,MORENO-ASPITIA A,et al.Phase Ⅰ study of panobinostat (LBH589) and letrozole in postmenopausal metastatic breast cancer patients［J］.Clin Breast Cancer,2016,16(2):82-86.
［25］ GIORDANO F,PAOLI A,FORASTIERO M,et al.Valproic acid inhibits cell growth in both MCF-7 and MDA-MB231 cells by triggering different responses in a cell type-specific manner［J］.J Transl Med,2023,21(1):165.
［26］ LIU G,WANG H,ZHANG F,et al.The effect of VPA on increasing radiosensitivity in osteosarcoma cells and primary-culture cells from chemical carcinogen-induced breast cancer in rats［J］.Int J Mol Sci,2017,18(5):1027.
［27］ YARDLEY DA,ISMAIL-KHAN RR,MELICHAR B,et al.Randomized phase Ⅱ,double-blind,placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal aromatase inhibitor［J］.J Clin Oncol,2013,31(17):2128-2135.
［28］ XU B,ZHANG Q,HU X,et al.Entinostat,a class I selective histone deacetylase inhibitor,plus exemestane for Chinese patients with hormone receptor-positive advanced breast cancer:A multicenter,randomized,double-blind,placebo-controlled,phase 3 trial［J］.Acta Pharm Sin B,2023,13(5):2250-2258.
［29］ MERINO VF,CHO S,NGUYEN N,et al.Induction of cell cycle arrest and inflammatory genes by combined treatment with epigenetic,differentiating,and chemotherapeutic agents in triple-negative breast cancer［J］.Breast Cancer Res,2018,20(1):145.
［30］ LI J.Chidamide enhances cytotoxicity of doxorubicin by promoting autophagy and apoptosis in breast cancer［J］.BMC Cancer,2023,23(1):353.
［31］ CAO L,ZHAO S,YANG Q,et al.Chidamide combined with doxorubicin induced p53-driven cell cycle arrest and cell apoptosis reverse multidrug resistance of breast cancer［J］.Front Oncol,2021,11:614458.
［32］ TU K,YU Y,WANG Y,et al.Combination of chidamide-mediated epigenetic modulation with immunotherapy:Boosting tumor immunogenicity and response to PD-1/PD-L1 blockade［J］.ACS Appl Mater Interfaces,2021,13(33):39003-39017.
［33］ JIANG Z,LI W,HU X,et al.Tucidinostat plus exemestane for postmenopausal patients with advanced,hormone receptor-positive breast cancer (ACE):a randomised,double-blind,placebo-controlled,phase 3 trial［J］.Lancet Oncol,2019,20(6):806-815.
［34］ 中国临床肿瘤学会指南工作委员会.中国临床肿瘤学会 (CSCO)乳腺癌诊疗指南 2023［M］.北京:人民卫生出版社,2023:104-105. Guidelines Working Committee of Chinese Society of Clinical Oncology.Chinese Society of Clinical Oncology (CSCO) guidelines for the diagnosis and treatment of breast cancer 2023［M］.Beijing:People's Health Publishing House，2023:104-105.

Memo

Memo:
National Natural Science Foundation of China(No.82272852);国家自然科学基金资助项目（编号：82272852）
Last Update: 1900-01-01